SCHEMBL8245260

SCHEMBL8245260

COc1ccc(N2CCN(Cc3ccc(/C=C/C(=O)NO)cc3)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 13/20 0.61
▸ HDAC8 Q9BY41 12/20 0.61
▸ HDAC3 O15379 11/20 0.61
▸ HDAC2 Q92769 11/20 0.61
▸ HDAC6 Q9UBN7 10/20 0.61
▸ HDAC10 Q969S8 8/20 0.59
▸ HDAC4 P56524 7/20 0.59
▸ HDAC7 Q8WUI4 7/20 0.59
▸ HDAC11 Q96DB2 7/20 0.59
▸ HDAC9 Q9UKV0 7/20 0.59
▸ HDAC5 Q9UQL6 7/20 0.59
▸ MAPT P10636 3/20 0.58
▸ KDM4E B2RXH2 1/20 0.58
▸ ACHE P22303 2/20 0.56
▸ BCHE P06276 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8246835 0.89 KDM4E (0.61) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL13949968 0.86 HDAC1 (0.61) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL18047171 0.83 HDAC8 (0.59) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL18047173 0.83 HDAC8 (0.59) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL13949927 0.81 DRD2 (0.67) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL23055097 0.81 MAPT (0.59) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL8241471 0.80 HDAC6 (0.86) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL9727332 0.80 SIGMAR1 (0.65) ACHEBCHEL3MBTL1
SCHEMBL9727336 0.80 SIGMAR1 (0.65) ACHEBCHEL3MBTL1
SCHEMBL17416855 0.79 HDAC1 (0.52) HDAC1HDAC8HDAC3HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed
US-20090012066-A1 Method of Use of Deacetylase Inhibitors NOVARTIS AG 2009-01-08 — — US disclosed
US-20090012066-A1 Method of Use of Deacetylase Inhibitors NOVARTIS AG 2009-01-08 — — US disclosed
US-20080176849-A1 DEACETYLASE INHIBITORS SECURA BIO, INC. 2008-07-24 — — US disclosed
US-20080176849-A1 DEACETYLASE INHIBITORS SECURA BIO, INC. 2008-07-24 — — US disclosed
WO-2007021682-A1 METHOD OF USE OF DEACETYLASE INHIBITORS NOVARTIS AG (CH) 2007-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC8 4/4885HDAC3 1/4885
US-20080176849-A1 DEACETYLASE INHIBITORS HDAC1, HDAC3, HDAC6 HDAC1 1/4885HDAC8 10/4885HDAC3 2/4885
US-20090012066-A1 Method of Use of Deacetylase Inhibitors HDAC3, HDAC5, HDAC1 HDAC1 3/4885HDAC8 8/4885HDAC3 1/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC8 4/4885HDAC3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback